



Published in final edited form as:

J Allergy Clin Immunol. 2016 September ; 138(3): 639–652. doi:10.1016/j.jaci.2016.06.003.

Regulatory T cells in Allergic Diseases

Magali Noval Rivas, PhD^a and Talal A. Chatila, MD, MSc^{b,c}

^aDivision of Pediatric Infectious Diseases and Immunology, Department of Pediatric, Infectious and Immunologic Diseases Research Center, Cedars-Sinai Medical Center, Los Angeles, CA

^bDivision of Immunology, Boston Children's Hospital, Boston, MA, USA

^cDepartment of Pediatrics, Harvard Medical School, Boston, MA, USA

Abstract

The pathogenesis of allergic diseases entails an ineffective tolerogenic immune response towards allergens. Regulatory T cells (T_{Reg}) cells play a key role in sustaining immune tolerance to allergens, yet mechanisms by which T_{Reg} cells fail to maintain tolerance in allergic diseases are not well understood. We review current concepts and established mechanisms regarding how T_{Reg} cells regulate different components of allergen-triggered immune responses to promote and maintain tolerance. We will also discuss more recent advances that emphasize the “dual” functionality of T_{Reg} cells in allergic diseases: how T_{Reg} cells are essential in promoting tolerance to allergens but also how a pro-allergic inflammatory environment can skew T_{Reg} cells towards a pathogenic phenotype that aggravates and perpetuates disease. These advances highlight opportunities for novel therapeutic strategies that aim to re-establish tolerance in chronic allergic diseases by promoting T_{Reg} cell and stability function.

Keywords

Asthma; Food Allergy; Regulatory T cells; FOXP3; Interleukin 4; T Helper cells type 2

Introduction

The increased prevalence in allergic diseases has become a major health problem in affluent and rapidly developing societies. Over the last 150 years, accelerated social and environmental changes augured by the industrial revolution, and which profoundly altered patterns of human activity, living arrangements, diet and infections, all came to influence the rise and severity of allergic disorders¹. In the USA, food allergy prevalence reaches up to 8% among children and 5% of the adult population whereas 8.6% of children and 7.4% of adults are affected by asthma^{2,3}. The dramatically increased burden of allergic diseases has exacted considerable morbidity on those suffering from those disorders and resulted in substantial financial costs incurred by affected individuals and their healthcare systems. While therapies for allergic diseases have improved over the years with the introduction of agents aimed at

Corresponding Author: Talal A. Chatila at the Division of Immunology, Boston Children's Hospital and the Department of Pediatrics, Harvard Medical School. Address: Karp Family Building, Room 10-214. 1 Blackfan Street, Boston, MA 02115, talal.chatila@childrens.harvard.edu, Phone number: 617- 919-3529.

combating the inflammatory processes as well as providing symptomatic relief, those therapies have remained for the most non-curative.

Allergic diseases arise in response to normally innocuous environmental agents, including aeroallergens and foods. They involve the participation of components of the innate and adaptive immune responses, such as innate lymphoid cells type 2 (ILC2) mast cells, basophils, eosinophils, as well as activated T helper type 2 (Th2) cells and B cells switched to the production of immunoglobulin type E (IgE)^{4,5}. Immune regulatory mechanisms normally operative to maintain tolerance to allergens breakdown for reasons that still remain obscure. The dramatic increase in prevalence of allergic disease during the past decades indicates a strong influence of environmental factors acting on genetically susceptible hosts to promote disease^{6,7}. Emerging studies emphasize the interaction of environmental factors, including diet, antibiotic usage and others, with components of the immune system, affecting their function and modify the outcome of the immune response⁸. They also support the idea that the commensal bacteria play a central role in the regulation of allergic diseases and that they dynamically interact with host genetic background and environmental factors to promote or disrupt oral tolerance⁹⁻¹¹. Genetic and immunological evidence also reinforce the idea of a pivotal role for regulatory T (T_{Reg}) cells in promoting tolerance to allergens and preventing allergic disorder¹²⁻¹⁶. In this review, we will discuss recent advances demonstrating the “dual potential” of T_{Reg} cells in allergic diseases; how T_{Reg} cells are beneficial in promoting tolerance but also how the pro-allergic environment can derange the T_{Reg} cell response to aggravate and perpetuates disease.

Natural and induced Foxp3⁺ T_{Reg} cells

T_{Reg} cells were initially described as a population of CD4⁺ T cells expressing the IL-2 receptor α chain (CD25) and CD45RB, able to protect mice from developing autoimmune diseases^{17,18}. Afterwards, the establishment of T_{Reg} cells as a distinct CD4⁺ T cells sub-population was empowered by the identification of the Forkhead winged helix transcription factor FOXP3 (Forkhead Box 3) as a specific T_{Reg} cell maker essential to their function^{19,20}. FOXP3 is required for the differentiation of T_{Reg} cells, evidenced by the generation of aberrant T_{Reg} cells lacking in regulatory function in mice with loss-of-function mutations in *Foxp3*^{21,22}. FOXP3 deficiency results in the development of a multi-organ lymphoproliferative autoimmune disease, referred to as Immune Dysregulation, Polyendocrinopathy, Enteropathy X-linked (IPEX) in human subjects and *scurfy* in mice^{12,23-26}. Expression of FOXP3 into human and murine conventional CD4⁺ Foxp3⁻ non-T_{Reg} cells by means of retroviral gene transfer, converts naïve T cells into T_{Reg} cells¹⁹. It is now well established that T_{Reg} cells enforce tolerance to both self-antigens and to the “extended-self”, the latter encompassing commensal flora and innocuous environmental antigens such as allergens [Reviewed in ²⁷⁻³⁰].

A major population of T_{Reg} cells arises in the thymus and is known as CD4⁺ FOXP3⁺ “natural” T_{Reg} (nT_{Reg}, also known as thymus-derived or tT_{Reg}) cells, which chiefly mediates tolerance to self-antigens³¹ (Fig 1). A second population of CD4⁺ FOXP3⁺ T_{Reg} cells arises extra-thymically in peripheral lymphoid tissues from a pool of naïve conventional CD4⁺ FOXP3⁻ T cells (T_{conv}) after exposure to antigens and in the presence of TGF- β [reviewed

in³²]. These induced T_{Reg} (iT_{Reg}, also known as peripheral or pT_{Reg}) cells are particularly enriched in the gastro-intestinal tract and in the lungs during chronic inflammation, with specificities directed against microbial antigens or environmental allergens³³⁻³⁵ (Fig 1). The generation of iT_{Reg} cells at the intestinal mucosa is facilitated by the large abundance of TGF- β and retinoic acid (RA), a vitamin A metabolite, both secreted by the CD103⁺ CD11c⁺ dendritic cells (DCs)³⁶⁻³⁸. In lung tissues, resident macrophages (CD45⁺ CD11c⁺ MHC class-II^{low} F4/80⁺) constitutively expressing TGF- β and RA are the main subset of cells driving iT_{Reg} cells induction from naïve CD4⁺ T_{conv} cells³⁹ (Fig 1). Both FOXP3⁺ nT_{Reg} and iT_{Reg} cells subsets play a key function in the maintenance of peripheral tolerance by suppressing reactivity to self-antigens and by containing the amplitude of immune responses to foreign antigens.

Because of their different origins, the TCR repertoires of thymic nT_{Reg} and peripheral iT_{Reg} cells are largely non-overlapping and biased towards self and non-self antigens, respectively⁴⁰. However, iT_{Reg} cells are known to be less stable than nT_{Reg} cells and under inflammatory conditions can lose FOXP3 expression (ex-T_{Reg}) and produce cytokines such as IFN- γ and IL-17^{41,42}. This lack of stability can be explained by the methylation status of the conserved non-coding region 2 (CNS2) of the *Foxp3* gene. The *FOXP3* CNS2 locus, which acts to maintain T_{Reg} cell lineage identity under inflammatory conditions, is known to be stably hypomethylated in nT_{Reg} whereas it is incompletely demethylated in iT_{Reg} cells⁴³⁻⁴⁶. One difficulty for the functional and genetic study of iT_{Reg} and nT_{Reg} cells is the lack of unique and specific markers allowing the distinction between those two populations and their identification *in vivo*. nT_{Reg} and iT_{Reg} cells express similar levels of shared T_{Reg} cell markers such FOXP3, CTLA-4, GITR, ICOS, CD103 and CD25. However, many of those markers are also up-regulated by activated CD4⁺ T cells under inflammatory conditions and their level of expression do not allow the distinction between nT_{Reg} and iT_{Reg} cells⁴⁷. The use of Helios and Neuropilin-1 (Nrp-1) has been proposed to specifically discriminate nT_{Reg} from iT_{Reg} cells, since the expression of those markers is higher in nT_{Reg} compared to iT_{Reg} cells⁴⁸⁻⁵⁰. While Nrp1 may be upregulated in the context of an inflammatory environment, Helios^{low} expression has been extensively used as an *in vivo* marker that distinguishes iT_{Reg} from nT_{Reg} cells⁵⁰⁻⁵².

In addition to FOXP3⁺ T_{Reg} cells, CD4⁺ type 1 T regulatory cells (Tr1) represent another subset of T_{Reg} cells defined by the expression of IL-10 and the surface marker LAG-3 and CD49b in the face of absent FOXP3 and CD25 expression⁵³. The relationship between FOXP3⁺ T_{Reg} cells and Tr1 cells remains obscure, with both subsets employing common effector pathways including IL-10, TGF- β and CTLA-4⁵⁴. Unlike FOXP3⁺ T_{Reg} cells, Tr1 cells are not uniquely defined by one transcription factor such as FOXP3, but express a number of transcription factors common to other T cell populations including c-MAF, Ahr (Aryl hydrocarbon receptor), and others⁵⁴. Many studies that have referred to IL-10 producing T_{Reg} cells as Tr1 cells did not discriminate between the two populations by appropriate staining for differentiating markers including FOXP3. In this review, we will focus on FOXP3⁺ T_{Reg} cells as their role in the regulation of allergic disease is far more well defined.

Mechanisms of T_{Reg} cells suppression

The suppressive functions of T_{Reg} cells are essential to control autoimmunity, allergic and inflammatory reactions and responses to infectious agents and tumors. Foxp3⁺ nT_{Reg} and iT_{Reg} cells are characterized by a non-overlapping TCR repertoire, resulting in a division of labour where nT_{Reg} and iT_{Reg} cells regulate immune responses targeting “self” antigens and “non-self” infectious or innocuous agents respectively^{40,55}. T_{Reg} cells suppressive function are mediated by multiple mechanisms that involve either the release of inhibitory cytokines (IL-10, TGF- β and IL-35)⁵⁶⁻⁵⁹ and cytolytic molecules (granzymes A and B)⁶⁰⁻⁶², or the down-modulation of antigen presenting cells (Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) and Lymphocyte-activation Gene 3 (LAG-3)^{63,64}, deprivation of trophic cytokines (IL-2 via CD25)⁶⁵ and modulation metabolic pathways (CD73 and CD39)⁶⁶ (Fig 2). Expression of select transcription factors and receptors enables T_{Reg} cells suppressive functions under inflammatory conditions. GATA-3 expression by T_{Reg} cells is triggered by TCR activation and is required to maintain FOXP3 expression and to allow accumulation of T_{Reg} cells at inflamed sites⁶⁷. More recently, it has been demonstrated that Helios expression by T_{Reg} cells is key to support their suppressive functions and phenotypic stability during inflammation⁶⁸. T_{Reg} cells functions can also be regulated by endogenous danger signals, or alarmins, released by epithelial cells at the mucosal barrier. Colonic T_{Reg} cells express the IL-33 receptor (ST2), allowing them to respond to epithelial cell IL-33 production resulting from tissue damage by amplifying their regulatory functions and restraining intestinal inflammation⁶⁹.

T_{Reg} cell role in tissue repair

In addition to their immunosuppressive functions and their capacities to restrict the intensity of immune responses, T_{Reg} cells can also control non-immunological process such as tissue repair resulting from extensive inflammation. Studies have identified the presence of T_{Reg} cells in a wide variety of non-lymphoid organs such as the skin, the intestinal mucosa, the lungs and visceral adipose tissues⁷⁰. In mice, T_{Reg} cells accumulate and remain in skeletal muscles after acute injury and their depletion results in increased muscle damage⁷¹. T_{Reg} cell production of Amphiregulin (Areg), an epidermal growth factor family member known to promote healing and tissue regeneration, in injured lung and muscle tissues appears to prevent the tissue damages^{71,72}.

T_{Reg} cells and allergic diseases

Allergic diseases reflect a failure to develop tolerance toward a specific allergen, provoking the emergence of an allergen-specific CD4⁺ T helper type 2 (Th2) cell response, the generation of allergen-specific immunoglobulin E (IgE) and the recruitment of effector cells to the GI tract or lung tissues^{4,73}. In humans, loss-of-function mutations affecting *FOXP3* result in the development of IPEX, characterized not only by autoimmunity but also severe allergic inflammation including atopic dermatitis, food allergy, asthma, elevated serum IgE levels and peripheral eosinophilia^{12,13,74}. *Foxp3* mutant mice spontaneously exhibit allergic airways inflammation, atopic-dermatitis skin-like disease and elevated serum IgE levels independently of their genetic background⁷⁵. By using another genetic murine model, the ‘DEREG’ mice which express the diphtheria toxin (DT) receptor under the control of the

Foxp3 gene, Hadis *et al.* have demonstrated that T_{Reg} cells depletion in OVA-tolerant DERE mice was sufficient to break oral tolerance⁷⁶. Furthermore, *in vivo* depletion of CD4⁺ CD25⁺ T cells in peanut sensitized mice by means of anti-CD25 monoclonal antibody results in impaired oral tolerance development and leads to an heightened allergic⁷⁷. The central role of T_{Reg} cells in oral tolerance development to food allergen has been confirmed in human studies where children who had outgrown milk allergy exhibited higher frequencies of milk protein-specific CD4⁺ CD25⁺ T_{Reg} cells and where the emergence of allergen-specific T_{Reg} cells is highly correlated with a favourable disease outcome^{78,79}.

Among the T_{Reg} cell populations, Foxp3⁺ iT_{Reg} cells play an essential role in maintaining tolerance at environmental interfaces, including small and large intestinal and the lung respiratory mucosa³². Allergen-specific iT_{Reg} cells are involved in controlling inflammation severity and the IL-4 Th2 cell immune response³⁵. Accordingly, the development of allergic reactions may result from decreased induction and/or impaired function of allergen-specific iT_{Reg} cells in genetically allergy-prone subjects. This proposition is supported by a study that took advantage of mice lacking *CNS1*, an intronic *Foxp3* enhancer which contains binding sites for multiple transcription factors such as NFAT and Smad3 and is required for the differentiation of iT_{Reg} cells *in vivo*^{80,81}. Despite decreased iT_{Reg} cells expansion, *CNS1*-deficient mice do not develop a fatal autoimmune lymphoproliferative disease. Nonetheless, with time *CNS1*-deficient mice develop a pro-allergic phenotype associated with Th2 cell-induced pathologies at mucosal surfaces⁸¹. We have recently demonstrated using mice with a gain of function mutation in the IL-4R α chain (*Il4raF709* mice) that heightens susceptibility to oral sensitization that food allergy development is associated with impaired generation and function of allergen-specific T_{Reg} cells⁸². In peanut allergic patients undergoing successful oral immunotherapy (OIT) leading to peanut tolerance induction demonstrated increased numbers of circulating allergen-specific iT_{Reg} cells with heighten suppressive capacities and augmented stability, as evidenced by increased demethylation of CpG islands within the *FOXP3* gene⁸³. Evidences also point towards a reduced frequency of T_{Reg} cells associated with allergic asthma^{84,85}. Compared to healthy controls, frequencies of pulmonary CD4⁺ CD25^{high} T_{Reg} cells in the bronchoalveolar lavage fluid (BALF) were significantly decreased in untreated asthmatic children⁸⁶. Four weeks of inhaled corticosteroid treatment were sufficient to restore the T_{Reg} cells compartment in the blood and the BALF⁸⁶.

A specific requirement for the cytokines IL-10 and TGF- β 1 expressed by T_{Reg} cells in the control of allergic responses has emerged. Kearley *et al.* have demonstrated that adoptively transferred allergen-specific T_{Reg} cell suppressive functions during allergic airway inflammation rely on their capacity to induce IL-10 production by CD4⁺ T cells⁸⁷. However, subsequent studies by Rubstov *et al.* employed a genetic approach to show that T_{Reg} cell-specific deletion of *Il10* promoted allergic airway inflammation; thereby suggesting that T_{Reg} cell-derived IL-10 plays a “privileged”, non-redundant role in the induction of immune tolerance in allergic airway inflammation⁸⁸. IL-10 has immunosuppressive functions and can modulate the activity of key cell subset involved in the allergic reaction such as mast cells^{82,89}, Th2 T cells⁹⁰, eosinophils and DCs⁹¹. The Similar to IL-10, TGF- β 1 specifically expressed by T_{Reg} cells also appears to play a privileged role in the regulation of allergic responses. In mice, T_{Reg} cell-specific deletion of *Tgfb1* heightens susceptibility to food

allergy (M. NR and T. A. C; unpublished data). The respective role of T_{Reg} cell IL-10 and TGF- β 1 in the regulation of different allergic responses remains to be fully mapped.

In addition to the defect in allergen-specific iT_{Reg} cell induction, aberrations of the T_{Reg} cell compartment during allergic disease can also be attributed to a decreased or failure of their suppressive functions. *In vitro* studies with peripheral T_{Reg} (CD4⁺CD25⁺) cells isolated from the blood of atopic and non-atopic patients demonstrated that atopic T_{Reg} cells can be distinguished from non-atopic T_{Reg} cells by decreased capacities to suppress allergen-driven proliferation of effector CD4⁺ T cells as well as their Th2 cell cytokines secretion⁹².

T_{Reg} cells regulation of the innate immune response in allergic diseases

T_{Reg} cells can exert their immunosuppressive functions on a broad variety of different cell types, including innate immune cells. Accumulating evidences demonstrate that T_{Reg} cells control the immediate hypersensitivity response by acting directly on mast cells and blocking their degranulation (Fig 3)^{82,89,93}. After allergen-sensitization, triggering of mucosal mast cells via the high affinity receptor for IgE (Fc ϵ RI) will induce the release of preformed mediators and elicit an IgE-mediated hypersensitivity response⁹⁴. One mechanism by which T_{Reg} cells modulate IgE-mediated mucosal mast cells degranulation and decrease mast cells effector mediators release is through the OX40-OX40L pathway⁹³. Direct cell-to-cell contact between OX40 expressed on T_{Reg} cells and OX40L on mast cells will lead to increased intracellular levels of cyclic adenosine monophosphate (cAMP) and result in a blockage of extracellular Ca²⁺ influx and mast cell mediator release inhibition⁹³.

IL-4 production by mast cells is critical in food allergic reaction. IgE interaction with the Fc ϵ RI expressed on mast cells act as amplifier of the Th2 cell and IgE responses during allergic sensitization⁸⁹. Importantly, dysregulated IgE mast cell activation and their subsequent IL-4 production profoundly inhibits allergen iT_{Reg} cells generation during allergic processes⁸². This IL-4 inhibition of iT_{Reg} cells generation is mediated through increased intracellular levels of GATA-3 which acts as a FOXP3 inhibitor in early T cell differentiation⁹⁵. In contrast, food allergy prone mice that lack the α chain of the high affinity IgE receptor Fc ϵ RI (*I4raF709* Fc ϵ 1 $\alpha^{-/-}$) were protected from anaphylaxis⁸². This protection was reflected in decreased mast cell expansion and degranulation and inhibition of the conventional CD4⁺ cell response, consistent with the key function of IgE/Fc ϵ RI axis in mediating not only anaphylaxis but also driving the food allergen-associated cell response^{82,89}. Moreover, Fc ϵ RI deficiency completely corrected the impaired allergen-specific iTreg cell generation⁸². Similar results were obtained by targeting IgE production (IgE^{-/-} mice or anti-IgE treatment) or by using mast cells ablation genetic murine models⁸⁹. The key role of T_{Reg} cells in inhibiting mast cell degranulation and their Th2 cell cytokine secretion is thus critical to the prevention of food allergy (Fig 3).

Innate lymphoid cells type 2 (ILC2), a population of mucosal innate cells, are simultaneously characterized by a lack of antigen specificity (absence of T and B cell receptor) and lymphoid traits, as demonstrated by a shared development origin and phenotypic traits with T cells⁹⁶. ILC2 produce large amounts of Th2 cell cytokines and are linked to allergic disorders such as asthma, chronic rhinosinusitis and atopic dermatitis⁹⁷⁻¹⁰⁰. In mice, ILC2 can be identified based on the expression of CD25 (IL-2R α),

IL-33R (ST2) and CD127 (IL-7R α)¹⁰¹. ILC2 are located in the blood and various organs such as the spleen, the gastrointestinal tract, the liver, the lungs and the lymph nodes^{102,103}. The transcription factor GATA-3 is required for ILC2 differentiation, their stability and Th2 cell cytokines production^{104,105}. Halim *et al.* demonstrated that ILC2 are required for the development of protease allergen papain-induced airway inflammation as ILC2 deficient mice (ROR $\alpha^{-/-}$) were incapable of mounting an effective Th2 cell immune response and had reduced type 2 lung inflammation¹⁰². The critical role of ILC2 in triggering Th2 cell adaptive immune responses involves their production of IL-13, which promotes migration of DC to the draining lymph nodes and enhance the conversion of naïve CD4⁺ T cells into Th2 cells¹⁰²

The role of ILC2 in food allergy has been less documented. It appears that IL-13 production by ILC2 enhances allergic mucosal inflammation and promotes IgE-mediated experimental food allergy¹⁰⁶. Food allergy development is associated with defective allergen-specific T_{Reg} cells induction, consequently resulting in disease promotion⁸². We have recently demonstrated that increased IL-33 production at the intestinal mucosa during food allergy promotes ILC2 expansion, which further enhances the IgE-mediated food allergic response through their IL-4 production¹⁰⁷. ILC2-derived IL-4 inhibits T_{Reg} cell response and promotes mast cells activation. Reciprocally, T_{Reg} cells block ILC2 expansion and suppress their IL-4 production¹⁰⁷(Fig 3). Together, these findings point to the disruption of T_{Reg} cell control of mast cells and ILC2 as a key mechanism in the pathogenesis of food allergy. At steady state, T_{Reg} cells control both mast cells and ILC2 by restricting their capacity to promote food allergy. Perturbation of this regulatory interaction will subsequently result in a dysregulated pro-allergic innate immune response skewing the immunological balance towards food allergy.

By processing and presenting antigens to naïve T cells, dendritic cells (DCs) are key initiators and master regulators of the allergen-specific immune response. T_{Reg} cells also directly act on DCs by down-modulating their surface expression of CD80/CD86 expression and subsequently blocking the generation of an allergen-specific Th2 cell immune response. T_{Reg} cell suppression of DCs appears to be mediated via CTLA-4, LAG-3 and Leukocyte Function-Associated antigen-1 (LFA-1)^{63,64,108}. DCs, mostly plasmacytoid DCs (pDCs) have the capacities to prime and naïve T cells and induced their differentiation into IL-10 secreting T_{Reg} cells upon ICOS-ICOS ligand interactions^{109,110}.

T_{Reg} cells regulation of the adaptive immune response in allergic diseases

Allergic disorders are characterized by increased dysregulated and aberrant immune responses mediated by the Th2 cell cytokines IL-5, IL-4 and IL-13. T_{Reg} cells have also the capacities to regulate allergen-induced adaptive T and B cells responses through diverse mechanisms, either soluble or membrane-bound suppressive molecules (Fig 4). T_{Reg} cells express constitutively CTLA-4, a negative co-stimulatory molecule which is essential to their suppressive functions. Mice deficient for CTLA-4 exhibit a lethal multi-organ lymphoproliferative disease¹¹¹. T_{Reg} cell-specific deletion of CTLA-4, by means of crossing *Foxp3-Cre* with *Ctla4^{fl/fl}* mice, leads to an autoimmune disease characterized by an increased Th2 cell immune response as evidenced by elevated IL-4 production by CD4⁺

Foxp3⁻ T_{conv} cells and increased serum IgE levels⁹¹. Ovalbumin (OVA)-specific nT_{Reg} cells are efficient in controlling *in vitro* Th2 cell immune responses and IL-4 production by inhibiting the polarization of naive CD4⁺ T cells into Th2 cells via a GITR-dependent suppressive mechanisms¹¹². Circulating CD4⁺ CD25⁺ T_{Reg} cells isolated from the blood of atopic human subjects were also less efficient *in vitro* than healthy controls CD4⁺ CD25⁺ T_{Reg} in controlling the Th2 cell cytokines production by effector CD4⁺ T cells⁹². Furthermore, frequencies of allergen-specific T_{Reg} cells secreting IL-10 with suppressive functions were predominant in peripheral blood mononuclear cells (PBMCs) from healthy subject whereas frequencies of Th2 CD4⁺ IL-4 secreting T cells frequencies were overrepresented in allergic subjects⁹⁰. Effector CD4⁺ IL4⁺ Th2 cells and suppressive T_{Reg} IL-10⁺ cells are present in both healthy and allergic patients, their ratio frequencies determine either tolerance induction or allergic response development⁹⁰.

Through their production of IgE, B cells are essential in the development of allergic immune responses. IgE responses are highly dependent of the immune response Th polarization; the Th2 cell cytokines IL-4 and IL-13 and CD40-CD40L cognate interactions are two signals required to class switching and IgE production by B cells¹¹³. *In vitro*, peripheral allergen-specific T_{Reg} cells from healthy subjects repress B cells IgE production by inducing IgG4 class switching¹¹⁴. T_{Reg} cells can also exercise their suppressive functions through the release of immunosuppressive cytokines such as IL-10, B cell suppression by T_{Reg} cells appears to be cell-to-cell contact mediated and probably occur via CTLA-4 and TGF-β1¹¹⁴.

Pathogenic T_{Reg} cell Th-reprogramming in allergic diseases

An important problem in chronic allergic diseases relates to the mechanisms that enable persistence of inflammation in the face of T_{Reg} cell responses¹¹⁵. In the course of regulating Th cell immune responses, T_{Reg} cells appropriate partial or “aborted” forms of the transcriptional programs of the target Th cells by expressing their master transcription factors, such as T-bet for Th1 cells and IRF-4 for Th2 cells, and co-opting their function^{116,117}. Whereas under physiological conditions such partial Th cell programming remains restrained, such restraint is lost under the influence of chronic inflammation leading to pathogenic reprogramming of T_{Reg} cells into Th cells^{118,119}. In the context of allergic diseases, emerging evidence indicates that a sharply skewed inflammatory environment can overcome the allergen-specific T_{Reg} cell regulatory response and redirect those cells towards a pathogenic and pro-inflammatory phenotype (Fig 5 and 6). Recent studies from our laboratory have provided two examples of how allergen-specific T_{Reg} cells may acquire T effector (T_{Eff}) cell programs and in the process contribute to disease pathogenesis. In the first set of studies, a tyrosine (Y) to phenylalanine (F) mutation at position 709 of the murine IL-4 receptor alpha chain (IL-4Rα) inactivated the receptor’s immunotyrosine inhibitory motif and resulted in augmented activation by IL-4 and IL-13 of the downstream transcription factor STAT6^{120,121}. This mutation, which models human polymorphisms that promote STAT6 activation via the IL-4Rα, imparted on mice heightened susceptibility to allergic diseases, including food allergy and allergic airway inflammation, and reproduced a Th2 cell-high disease “endotype” common in some subjects with those disorders. Importantly, allergen-specific T_{Reg} cells became reprogrammed to express a Th2 cell-like

phenotype, including IL-4 production, all the while retaining their Foxp3 expression⁸². Whereas the Th2 cell master transcription factor GATA-3 normally plays a positive role in the accumulation of T_{Reg} cells at sites of inflammation and prevents their polarization into Th17 cells, its abnormally expression in T_{Reg} cells may contribute to their Th2 cell-like reprogramming under conditions of intense cell polarization^{67,122,123}. The significance of this reprogramming was underlined by the observation that T_{Reg} cell-specific deletion of the *Ii4/Ii13* genes restrained the induction of food allergy and allergic airway inflammation in these mice⁸². Consistent with these results, human food allergic subjects manifest increase expression of Th2 cell cytokines in their circulating allergen-specific T_{Reg} cells, indicative of their acquisition of a “Th2-cell like” T_{Eff} phenotype⁸². Oral immunotherapy was associated with reversal of TH2 cell-like reprogramming of allergen-specific T_{Reg} cells, which is coincident with their improved suppression function (data not shown).

A second example of allergen-specific T_{Reg} cell reprogramming came from studies on a human IL-4R α allele that bears a glutamine (Q) to an arginine (R) substitution at position 576 (IL-4R α -Q576R)¹²⁴. This allele is associated with asthma severity, while introduction of the Q576R substitution into the murine IL-4R α results in exaggerated allergic airway inflammation when the mice are sensitized then challenged in their airways with allergens¹²⁵⁻¹²⁷ (Fig 6). Signalling via IL-4R α -Q576R allele does not impact the activation by the IL-4R of its dedicated transcription factor STAT6, and Th2 cell responses promoted via the IL-4R are preserved. Nevertheless, in both humans and mice, the Q576R substitution acts to create a novel branch of signalling via IL-4R α that activates microtubule-associated protein kinases (MAPK), leading to the induction by IL-4 of IL-6 production¹²⁸ (Fig 6). The newly produced IL-6 destabilizes newly formed allergen-specific T_{Reg} cells towards the Th17 cell lineage, thus giving rise to mixed Th2-Th17 cell responses in the context of allergic inflammation¹²⁸. Inhibition of the capacity of allergen-specific T_{Reg} cells to differentiate into Th17 cells, whether by neutralization of IL-6 or by T_{Reg} cell-specific deletion of genes encoding IL-6 receptor alpha chain (*Il6ra*) or the Th17 cell master transcription factor ROR γ t, reversed the exaggerated allergic inflammation induced by IL-4R α -Q576Rmice¹²⁸ (Fig 6).

Microbiome – T_{Reg} cell interactions in allergic diseases

Altered environmental exposures early in life may play a critical role in setting in motion the atopic diseases of childhood¹²⁹. The “hygiene hypothesis” stipulates that increased allergic rates observed over the years result from reduced microbial exposures arising from lifestyle changes, such as family size reduction, use of antibiotics and improved hygiene¹³⁰. The influence of the intestinal microbiome in tolerance induction and allergies development is becoming more appreciated. The intestinal colonization of neonates starts at birth from the mother’s vaginal flora, as the microbiota composition of vaginally delivered infants is similar to the maternal vagina¹³¹. Infants born by cesarian section have a different microbiota composition, mostly derived from maternal skin, and are at increased risks of developing asthma and allergy¹³². The first months of life are a critical period for the intestinal flora to settle and stabilize as children exhibiting intestinal dysbiosis in this “time-window” are at increased risks of developing asthma¹³³. Exposure to a farm environment and the associated subsequent large diversity of environmental microbial signals reduce the

risk of developing allergies^{133,134}. The importance of the microbial flora for allergic diseases development is further emphasized by the observation that Germ Free (GF) mice cannot be tolerized to oral antigens and develop a Th2 cell-biased immune response¹³⁵. In humans, a polymorphism in the promoter of CD14, a high affinity receptor for bacterial lipopolysaccharide (LPS) and co-receptor of TLR-4, has been associated with the development of atopic disease¹³⁶. Food allergic responses are also aggravated in TLR4^{-/-} mice or WT mice treated with antibiotics and repopulation of commensal flora in antibiotics treated mice result in reduced allergen-specific IgE and Th2 cell cytokines responses¹³⁷. These observations highlighted an important function of the intestinal microbial flora and microbial exposure in maintaining and shaping the immune response and inducing protection against the development of atopy^{138,139}.

By using *I4raF709* food allergy-prone mice, we have demonstrated that food allergy is associated with the emergence of an altered intestinal microbial flora¹⁰. The microbiome of allergic *I4raF709* mice exhibits decreased relative abundances of members from the Firmicutes phylum and increased abundance of bacteria belonging to the Proteobacteria phylum. Adoptive transfer of allergen-specific T_{Reg} cells prevented the development of food allergy in allergic-prone mice as well as the emergence of the food-allergy associated microbial dysbiosis¹⁰. Importantly, disease susceptibility can be transferred from allergic *I4raF709* mice to GF mice via transplantation of commensal flora from allergic donors. Allergy susceptibility transfer was associated with increase allergen-specific IgE production and expansion of IL-4 secreting Th2 CD4⁺ T cells in GF mice reconstituted with the allergic microbial flora¹⁰.

The commensal flora can target different immune cell subsets belonging to either the innate or/and adaptive allergic effector responses (Fig 7). In the steady-state, the microbial flora promotes intestinal IgA production by a T_{Reg} cell intrinsic MyD88-dependent mechanism that enables the generation of iT_{Reg} cells in the gut and their differentiation into T follicular helper cells (T_{FH})¹⁴⁰. Depletion of the commensal flora by antibiotic treatment¹⁴¹ or the use of GF mice¹¹ is associated with the development of Th2 cell-type allergic responses and higher serum IgE levels. Th2 cell-type allergic immune responses were held in check by MyD88-dependent microbial sensing by B cells, which suppressed the IgE responses¹⁴¹. The commensal microbiota also influence the outcome of the allergic response modulating the ILC (Fig 7). Mono-colonization of GF mice with anaerobic bacteria belonging to the Clostridia class blocks and protects from oral allergen sensitization by inducing IL22⁺ ROR- γ ⁺ ILC at the intestinal mucosa¹¹. ILC2 are expanding in the course of allergic disorders and have a pathogenic function in further promoting disease through their Th2 cell type cytokines secretion^{102,107}. However, how the intestinal or the upper airways microbial flora could affect, regulate or promote the ILC2 immune response needs still to be further investigated.

The microbiota promotes either a tolerant or a pro-Th2 cell type allergic immune response by interacting directly with immune cells and their TLRs or indirectly through the release of microbial products. Polysaccharide A (PSA), produced by the commensal bacterium *Bacteroides fragilis*, acts by a TLR2-dependent mechanisms to induce the conversion of CD4⁺ T cells into functional iT_{Reg} cells with enhanced suppressive activities and increased

IL-10 production^{142,143}. In mice, Clostridial species are among the most abundant Gram-positive bacteria present at the intestinal mucosa. Colonization of GF mice with a mix of Clostridium isolated from either murine or human faeces resulted in a strong induction of iT_{Reg} cells in the colonic lamina propria of the reconstituted mice^{144,145}. Through their production of IL-10, Clostridium-induced T_{Reg} cells also controlled the systemic IgE production by reducing *in vitro* the IL-4 production by splenic CD4⁺ T cells¹⁴⁴.

Short chain fatty acids (SCFAs) produced by bacterial fermentation of dietary fibers act on T cells via a G protein coupled receptor (GPR43) and protect mice from intestinal inflammation by expanding the pool of the colonic T_{Reg} cells¹⁴⁶. SCFAs also promote the generation of intestinal iT_{Reg} cells from naïve CD4⁺ T cells by T-cell intrinsic epigenetic mechanisms^{147,148}. Butyrate, a SCFA known as an histone deacetylase (HDAC) inhibitor, increases Foxp3 protein acetylation conferring thereby increased stability and enhanced suppressive function to *de novo* generated intestinal iT_{Reg} cells¹⁴⁸. Accordingly, a high-fiber diet results in modulation of the intestinal flora composition characterized by increased Bacteroidetes and decreased Firmicutes abundances, resulting in increased circulating levels of SCFAs and allergic airways inflammation protection¹⁴⁹. More recently, it has been reported that the microbiome and oral antigen promote the induction of iT_{Reg} cells expressing ROR γ t at the intestinal mucosal surfaces¹⁵⁰. Specific ablation of ROR γ t in T_{Reg} cells resulted in increased frequencies of GATA-3⁺ Foxp3⁺ T_{Reg} cells and increased production of IL-4 and IL-13 by CD4⁺ Foxp3⁻ T_{conv} cells, leading to the conclusion that the microbiome control the Th2 cell immune response through the expansion of T_{Reg} ROR γ t⁺ cells and the regulation of DC activation¹⁵⁰. Whether “pro-allergic” or “pro-tolerant” bacterial species are linked to and directly affect the generation of those GATA3⁺ or ROR γ t⁺ T_{Reg} cells needs to be further investigated. Since atopic disease are associated with a defect in the generation of allergen-specific iT_{Reg} cells, it will be of interest to pursue investigation of these pathways to identify potential therapeutic targets to promote allergen-specific tolerance.

Conclusion

A dynamic view of T_{Reg} cells in allergic disease is emerging in which they play a central, determining role not only in tolerance induction but also, when destabilized and reprogrammed, in mediating disease pathogenesis, severity and chronicity. Novel approaches to the re-establishment of tolerance are suggested by the results of preclinical models in which reinforcement of iT_{Reg} cell stability by interrupting their pathogenic programming may be of therapeutic benefit in these disorders.

Acknowledgments

This work was supported by the National Institutes of Health (5R01AI065617 and 1R56AI117983), to T.A.C.

Abbreviations

T_{Reg}	Regulatory T cells
BALF	Bronchoalveolar Lavage Fluid

ILC	innate lymphoid cells
Th	T helper
IgE	Immunoglobulin type E
Areg	Amphiregulin
Ahr	Aryl hydrocarbon receptor
SCFA	Short Chain Fatty Acids
HDAC	Histone Deacetylase
T_{Eff}	T effector cells
T_{Conv}	Conventional T cells
DCs	dendritic cells
APCs	antigen presenting cells
CTLA-4	Cytotoxic T Lymphocyte Antigen 4
LAG3	Lymphocyte-Activation Gene 3
TCR	T cell receptor
Tr1	Type 1 T regulatory cells

REFERENCES

1. Platts-Mills TAE. The allergy epidemics: 1870-2010. *J Allergy Clin Immunol.* 2015; 136:3–13. [PubMed: 26145982]
2. Sicherer SH, Sampson HA. Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment. *J Allergy Clin Immunol.* 2014; 133:291–307. quiz308. [PubMed: 24388012]
3. Loftus PA, Wise SK. Epidemiology of asthma. *Curr Opin Otolaryngol Head Neck Surg.* 2016; 24:245–9. [PubMed: 26977741]
4. Lambrecht BN, Hammad H. The immunology of asthma. *Nat Immunol.* 2014; 16:45–56. [PubMed: 25521684]
5. Sicherer SH, Sampson HA. Food allergy. *J Allergy Clin Immunol.* 2010; 125:S116–25. [PubMed: 20042231]
6. Sicherer SH. Epidemiology of food allergy. *J Allergy Clin Immunol.* 2011; 127:594–602. [PubMed: 21236480]
7. Fujimura KE, Lynch SV. Microbiota in allergy and asthma and the emerging relationship with the gut microbiome. *Cell Host and Microbe.* 2015; 17:592–602. [PubMed: 25974301]
8. Hong X, Wang X. Early life precursors, epigenetics, and the development of food allergy. *Semin Immunopathol.* 2012; 34:655–69. [PubMed: 22777545]
9. Feehley T, Stefka AT, Cao S, Nagler CR. Microbial regulation of allergic responses to food. *Semin Immunopathol.* 2012; 34:671–88. [PubMed: 22941410]
10. Noval Rivas M, Burton OT, Wise P, Zhang Y-Q, Hobson SA, Garcia Lloret M, et al. A microbiota signature associated with experimental food allergy promotes allergic sensitization and anaphylaxis. *J Allergy Clin Immunol.* 2013; 131:201–12. [PubMed: 23201093]
11. Stefka AT, Feehley T, Tripathi P, Qiu J, McCoy K, Mazmanian SK, et al. Commensal bacteria protect against food allergen sensitization. *PNAS.* 2014; 111:13145–50. [PubMed: 25157157]

12. Chatila TA, Blaeser F, Ho N, Lederman HM, Voulgaropoulos C, Helms C, et al. JM2, encoding a fork head–related protein, is mutated in X-linked autoimmunity–allergic dysregulation syndrome. *J Clin Invest*. 2000; 106:R75–R81. [PubMed: 11120765]
13. Torgerson TR, Linane A, Moes N, Anover S, Mateo V, Rieux Laucat F, et al. Severe food allergy as a variant of IPEX syndrome caused by a deletion in a noncoding region of the FOXP3 gene. *Gastroenterology*. 2007; 132:1705–17. [PubMed: 17484868]
14. Palomares O, Yaman G, Azkur AK, Akkoc T, Akdis M, Akdis CA. Role of Treg in immune regulation of allergic diseases. *Eur J Immunol*. 2010; 40:1232–40. [PubMed: 20148422]
15. Jones SM, Burks AW, Dupont C. State of the art on food allergen immunotherapy: oral, sublingual, and epicutaneous. *J Allergy Clin Immunol*. 2014; 133:318–23. [PubMed: 24636471]
16. Palomares O, Martín-Fontecha M, Lauener R, Traidl-Hoffmann C, Cavkaytar O, Akdis M, et al. Regulatory T cells and immune regulation of allergic diseases: roles of IL-10 and TGF- β . *Genes Immun*. 2014; 15:511–20. [PubMed: 25056447]
17. Sakaguchi S, Takahashi T, Nishizuka Y. Study on cellular events in post-thymectomy autoimmune oophoritis in mice. II. Requirement of Lyt-1 cells in normal female mice for the prevention of oophoritis. *J Exp Med*. 1982; 156:1577–86. [PubMed: 6983558]
18. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α -chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. *J Immunol*. 1995; 155:1151–64. [PubMed: 7636184]
19. Hori S. Control of Regulatory T Cell Development by the Transcription Factor Foxp3. *Science*. 2003; 299:1057–61. [PubMed: 12522256]
20. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. *Nat Immunol*. 2003; 4:330–6. [PubMed: 12612578]
21. Lin W, Haribhai D, Relland LM, Truong N, Carlson MR, Williams CB, et al. Regulatory T cell development in the absence of functional Foxp3. *Nat Immunol*. 2007; 8:359–68. [PubMed: 17273171]
22. Gavin MA, Rasmussen JP, Fontenot JD, Vasta V, Manganiello VC, Beavo JA, et al. Foxp3-dependent programme of regulatory T-cell differentiation. *Nature*. 2007; 445:771–5. [PubMed: 17220874]
23. Lyon MF, Peters J, Glenister PH, Ball S, Wright E. The scurfy mouse mutant has previously unrecognized hematological abnormalities and resembles Wiskott-Aldrich syndrome. *PNAS*. 1990; 87:2433–7. [PubMed: 2320565]
24. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. *Nat Genet*. 2001; 27:20–1. [PubMed: 11137993]
25. Brunkow ME, Jeffery EW, Hjerrild KA, Paepfer B, Clark LB, Yasayko SA, et al. Disruption of a new forkhead/winged-helix protein, scurfy, results in the fatal lymphoproliferative disorder of the scurfy mouse. *Nat Genet*. 2001; 27:68–73. [PubMed: 11138001]
26. Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL, Buist N, et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. *Nat Genet*. 2001; 27:18–20. [PubMed: 11137992]
27. Alroqi FJ, Chatila TA. T Regulatory Cell Biology in Health and Disease. *Curr Allergy Asthma Rep*. 2016; 16:27–8. [PubMed: 26922942]
28. Chatila TA. Regulatory T cells: key players in tolerance and autoimmunity. *Endocrinol Metab Clin North Am*. 2009; 38:265–72. [PubMed: 19328410]
29. Josefowicz SZ, Lu L-F, Rudensky AY. Regulatory T Cells: Mechanisms of Differentiation and Function. *Annu Rev Immunol*. 2012; 30:531–64. [PubMed: 22224781]
30. Benoist C, Mathis D. Treg cells, life history, and diversity. *Cold Spring Harb Perspect Biol*. 2012; 4:a007021. [PubMed: 22952391]
31. Lio C-WJ, Hsieh C-S. Becoming self-aware: the thymic education of regulatory T cells. *Curr Opin Immunol*. 2011; 23:213–9. [PubMed: 21146972]
32. Bilate AM, Lafaille JJ. Induced CD4 +Foxp3 +Regulatory T Cells in Immune Tolerance. *Annu Rev Immunol*. 2012; 30:733–58. [PubMed: 22224762]

33. Mucida D, Kutchukhidze N, Erazo A, Russo M, Lafaille J, Curotto de Lafaille M. Oral tolerance in the absence of naturally occurring Tregs. *J Clin Invest*. 2005; 115:1923–33. [PubMed: 15937545]
34. Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig MC, Boehmer von H. Inducing and expanding regulatory T cell populations by foreign antigen. *Nat Immunol*. 2005; 6:1219–27. [PubMed: 16244650]
35. Curotto de Lafaille MA, Kutchukhidze N, Shen S, Ding Y, Yee H, Lafaille JJ. Adaptive Foxp3+ Regulatory T Cell-Dependent and -Independent Control of Allergic Inflammation. *Immunity*. 2008; 29:114–26. [PubMed: 18617425]
36. Sun C-M, Hall JA, Blank RB, Bouladoux N, Oukka M, Mora JR, et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. *J Exp Med*. 2007; 204:1775–85. [PubMed: 17620362]
37. Siddiqui KRR, Powrie F. CD103+ GALT DCs promote Foxp3+ regulatory T cells. *Mucosal Immunol*. 2008; 1:S34–8. [PubMed: 19079226]
38. Lathrop SK, Bloom SM, Rao SM, Nutsch K, Lio C-W, Santacruz N, et al. Peripheral education of the immune system by colonic commensal microbiota. *Nature*. 2011; 478:250–4. [PubMed: 21937990]
39. Soroosh P, Doherty TA, Duan W, Mehta AK, Choi H, Adams YF, et al. Lung-resident tissue macrophages generate Foxp3+ regulatory T cells and promote airway tolerance. *J Exp Med*. 2013; 210:775–88. [PubMed: 23547101]
40. Haribhai D, Lin W, Edwards B, Ziegelbauer J, Salzman NH, Carlson MR, et al. A Central Role for Induced Regulatory T Cells in Tolerance Induction in Experimental Colitis. *J Immunol*. 2009; 182:3461–8. [PubMed: 19265124]
41. Zhou X, Bailey-Bucktrout SL, Jeker LT, Penaranda C, Martínez-Llordella M, Ashby M, et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. *Nat Immunol*. 2009; 10:1000–7. [PubMed: 19633673]
42. Yang XO, Nurieva R, Martinez GJ, Kang HS, Chung Y, Pappu BP, et al. Molecular Antagonism and Plasticity of Regulatory and Inflammatory T Cell Programs. *Immunity*. 2008; 29:44–56. [PubMed: 18585065]
43. Floess S, Freyer J, Siewert C, Baron U, Olek S, Polansky J, et al. Epigenetic Control of the foxp3 Locus in Regulatory T Cells. *PLoS Biol*. 2007; 5:0169–78.
44. Ohkura N, Kitagawa Y, Sakaguchi S. Development and Maintenance of Regulatory T cells. *Immunity*. 2013; 38:414–23. [PubMed: 23521883]
45. Feng Y, Arvey A, Chinen T, van der Veeken J, Gasteiger G, Rudensky AY. Control of the inheritance of regulatory T cell identity by a cis element in the Foxp3 locus. *Cell*. 2014; 158:749–63. [PubMed: 25126783]
46. Li X, Liang Y, LeBlanc M, Benner C, Zheng Y. Function of a Foxp3 cis-element in protecting regulatory T cell identity. *Cell*. 2014; 158:734–48. [PubMed: 25126782]
47. Herrath von MG, Harrison LC. Regulatory Lymphocytes: Antigen-induced regulatory T cells in autoimmunity. *Nat Rev Immunol*. 2003; 3:223–32. [PubMed: 12658270]
48. Weiss JM, Bilate AM, Gobert M, Ding Y, Curotto de Lafaille MA, Parkhurst CN, et al. Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not mucosa-generated induced Foxp3+ T reg cells. *J Exp Med*. 2012; 209:1723–42. [PubMed: 22966001]
49. Yadav M, Louvet C, Davini D, Gardner JM, Martinez-Llordella M, Bailey-Bucktrout S, et al. Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. *J Exp Med*. 2012; 209:1713–22. [PubMed: 22966003]
50. Thornton AM, Korty PE, Tran DQ, Wohlfert EA, Murray PE, Belkaid Y, et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. *J Immunol*. 2010; 184:3433–41. [PubMed: 20181882]
51. Feuerer M, Hill JA, Kretschmer K, Boehmer von H, Mathis D, Benoist C. Genomic definition of multiple ex vivo regulatory T cell subphenotypes. *PNAS*. 2010; 107:5919–24. [PubMed: 20231436]

52. Kim YC, Bhairavabhotla R, Yoon J, Golding A, Thornton AM, Tran DQ, et al. Oligodeoxynucleotides stabilize Helios-expressing Foxp3⁺ human T regulatory cells during in vitro expansion. *Blood*. 2012; 119:2810–8. [PubMed: 22294730]
53. Gagliani N, Magnani CF, Huber S, Gianolini ME, Pala M, Licona-Limón P, et al. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. *Nature Med*. 2013; 19:739–46. [PubMed: 23624599]
54. Gregori S, Goudy KS, Roncarolo MG. The cellular and molecular mechanisms of immunosuppression by human type 1 regulatory T cells. *Front Immunol*. 2012; 3:30. [PubMed: 22566914]
55. Haribhai D, Williams JB, Jia S, Nickerson D, Schmitt EG, Edwards B, et al. A Requisite Role for Induced Regulatory T Cells in Tolerance Based on Expanding Antigen Receptor Diversity. *Immunity*. 2011; 35:109–22. [PubMed: 21723159]
56. Kitani A, Fuss I, Nakamura K, Kumaki F, Usui T, Strober W. Transforming growth factor (TGF)-beta1-producing regulatory T cells induce Smad-mediated interleukin 10 secretion that facilitates coordinated immunoregulatory activity and amelioration of TGF-beta1-mediated fibrosis. *J Exp Med*. 2003; 198:1179–88. [PubMed: 14557415]
57. Nakamura K, Kitani A, Fuss I, Pedersen A, Harada N, Nawata H, et al. TGF- 1 Plays an Important Role in the Mechanism of CD4+CD25+ Regulatory T Cell Activity in Both Humans and Mice. *J Immunol*. 2004; 172:834–42. [PubMed: 14707053]
58. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. *Nature*. 2007; 450:566–9. [PubMed: 18033300]
59. Collison LW, Chaturvedi V, Henderson AL, Giacomini PR, Guy C, Bankoti J, et al. IL-35-mediated induction of a potent regulatory T cell population. *Nat Immunol*. 2010; 11:1093–101. [PubMed: 20953201]
60. McHugh R, Whitters M, A PC, Young D, Skevach EM, Collins M, et al. Immunoregulatory T Cells: Gene Expression Analysis Reveals a Functional Role for the Glucocorticoid-Induced TNF Receptor. *Immunity*. 2002; 16:311–23. [PubMed: 11869690]
61. Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. *Immunity*. 2004; 21:589–601. [PubMed: 15485635]
62. Gondek DC, Lu LF, Quezada SA, Sakaguchi S, Noelle RJ. Cutting Edge: Contact-Mediated Suppression by CD4+CD25+ Regulatory Cells Involves a Granzyme B-Dependent, Perforin-Independent Mechanism. *J Immunol*. 2005; 174:1783–6. [PubMed: 15699103]
63. Read S, Malmström V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. *J Exp Med*. 2000; 192:295–302. [PubMed: 10899916]
64. Liang B, Workman C, Lee J, Chew C, Dale BM, Colonna L, et al. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. *J Immunol*. 2008; 180:5916–26. [PubMed: 18424711]
65. Thornton A, Shevach EM. Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production. *J Immunol*. 1998; 188:287–96.
66. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. *J Exp Med*. 2007; 204:1257–65. [PubMed: 17502665]
67. Wohlfert EA, Grainger JR, Bouladoux N, Konkel JE, Oldenhove G, Ribeiro CH, et al. GATA3 controls Foxp3⁺ regulatory T cell fate during inflammation in mice. *J Clin Invest*. 2011; 121:4503–15. [PubMed: 21965331]
68. Kim H-J, Barnitz RA, Kreslavsky T, Brown FD, Moffett H, Lemieux ME, et al. Stable inhibitory activity of regulatory T cells requires the transcription factor Helios. *Science*. 2015; 350:334–9. [PubMed: 26472910]
69. Schiering C, Krausgruber T, Chomka A, Fröhlich A, Adelmann K, Wohlfert EA, et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. *Nature*. 2014; 513:564–8. [PubMed: 25043027]
70. Burzyn D, Benoist C, Mathis D. Regulatory T cells in nonlymphoid tissues. *Nat Immunol*. 2013; 14:1007–13. [PubMed: 24048122]

71. Burzyn D, Kuswanto W, Kolodin D, Shadrach JL, Cerletti M, Jang Y, et al. A special population of regulatory T cells potentiates muscle repair. *Cell*. 2013; 155:1282–95. [PubMed: 24315098]
72. Arpaia N, Green JA, Moltedo B, Arvey A, Hemmers S, Yuan S, et al. A Distinct Function of Regulatory T Cells in Tissue Protection. *Cell*. 2015; 162:1078–89. [PubMed: 26317471]
73. Berin CM, Shreffler WG. Mechanisms Underlying Induction of Tolerance to Foods. *Immunol Allergy Clin N Am*. 2016; 36:87–102.
74. Verbsky JW, Chatila TA. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) and IPEX-related disorders: an evolving web of heritable autoimmune diseases. *Curr Opin Pediatr*. 2013; 25:708–14. [PubMed: 24240290]
75. Lin W, Truong N, Grossman WJ, Haribhai D, Williams CB, Wang J, et al. Allergic dysregulation and hyperimmunoglobulinemia E in Foxp3 mutant mice. *J Allergy Clin Immunol*. 2005; 116:1106–15. [PubMed: 16275384]
76. Hadis U, Wahl B, Schulz O, Hardtke-Wolenski M, Schippers A, Wagner N, et al. Intestinal tolerance requires gut homing and expansion of FoxP3+ regulatory T cells in the lamina propria. *Immunity*. 2011; 34:237–46. [PubMed: 21333554]
77. van Wijk F, Wehrens E, Boon L, Pieters R, Knipels LM. CD4+CD25+ T cells regulate the intensity of hypersensitivity responses to peanut, but are not decisive in the induction of oral sensitization. *Clin Exp Allergy*. 2007; 37:572–81. [PubMed: 17430355]
78. Karlsson MR. Allergen-responsive CD4+CD25+ Regulatory T Cells in Children who Have Outgrown Cow's Milk Allergy. *J Exp Med*. 2004; 199:1679–88. [PubMed: 15197226]
79. Shreffler WG, Wanich N, Moloney M, Nowak-Węgrzyn A, Sampson HA. Association of allergen-specific regulatory T cells with the onset of clinical tolerance to milk protein. *J Allergy Clin Immunol*. 2009; 123:43–7. [PubMed: 19130927]
80. Tone Y, Furuuchi K, Kojima Y, Tykocinski ML, Greene MI, Tone M. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. *Nat Immunol*. 2007; 9:194–202. [PubMed: 18157133]
81. Josefowicz SZ, Niec RE, Kim HY, Treuting P, Chinen T, Zheng Y, et al. Extrathymically generated regulatory T cells control mucosal TH2 inflammation. *Nature*. 2012; 482:395–9. [PubMed: 22318520]
82. Noval Rivas M, Burton OT, Wise P, Charbonnier L-M, Georgiev P, Oettgen HC, et al. Regulatory T Cell Reprogramming toward a Th2-Cell-like Lineage Impairs Oral Tolerance and Promotes Food Allergy. *Immunity*. 2015; 42:512–23. [PubMed: 25769611]
83. Syed A, Garcia MA, Lyu S-C, Bucayu R, Kohli A, Ishida S, et al. Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). *J Allergy Clin Immunol*. 2014; 133:500–10. [PubMed: 24636474]
84. Mamessier E, Nieves A, Lorec AM, Dupuy P, Pinot D, Pinet C, et al. T-cell activation during exacerbations: a longitudinal study in refractory asthma. *Allergy*. 2008; 63:1202–10. [PubMed: 18699937]
85. Lloyd CM, Hawrylowicz CM. Regulatory T cells in asthma. *Immunity*. 2009; 31:438–49. [PubMed: 19766086]
86. Hartl D, Koller B, Mehlhorn AT, Reinhardt D, Nicolai T, Schendel DJ, et al. Quantitative and functional impairment of pulmonary CD4+CD25hi regulatory T cells in pediatric asthma. *J Allergy Clin Immunol*. 2007; 119:1258–66. [PubMed: 17412402]
87. Kearley J, Barker JE, Robinson DS, Lloyd CM. Resolution of airway inflammation and hyperreactivity after in vivo transfer of CD4 +CD25 +regulatory T cells is interleukin 10 dependent. *J Exp Med*. 2005; 202:1539–47. [PubMed: 16314435]
88. Rubtsov YP, Rasmussen JP, Chi EY, Fontenot J, Castelli L, Ye X, et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. *Immunity*. 2008; 28:546–58. [PubMed: 18387831]
89. Burton OT, Rivas MN, Zhou JS, Logsdon SL, Darling AR, Koleoglou KJ, et al. Immunoglobulin E Signal Inhibition during Allergen Ingestion Leads to Reversal of Established Food Allergy and Induction of Regulatory T Cells. *Immunity*. 2014; 41:141–51. [PubMed: 25017467]
90. Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Cramer R, et al. Immune Responses in Healthy and Allergic Individuals Are Characterized by a Fine Balance between

- Allergen-specific T Regulatory 1 and T Helper 2 Cells. *J Exp Med*. 2004; 199:1567–75. [PubMed: 15173208]
91. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al. CTLA-4 control over Foxp3+ regulatory T cell function. *Science*. 2008; 322:271–5. [PubMed: 18845758]
 92. Ling EM, Smith T, Nguyen XD, Pridgeon C, Dallman M, Arbery J, et al. Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. *Lancet*. 2004; 363:608–15. [PubMed: 14987885]
 93. Gri G, Piconese S, Frossi B, Manfroi V, Merluzzi S, Tripodo C, et al. CD4+CD25+ Regulatory T Cells Suppress Mast Cell Degranulation and Allergic Responses through OX40-OX40L Interaction. *Immunity*. 2008; 29:771–81. [PubMed: 18993084]
 94. Galli SJ, Tsai M. IgE and mast cells in allergic disease. *Nature Med*. 2012; 18:693–704. [PubMed: 22561833]
 95. Mantel P-Y, Kuipers H, Boyman O, Rhyner C, Ouaked N, Rückert B, et al. GATA3-driven Th2 responses inhibit TGF-beta1-induced FOXP3 expression and the formation of regulatory T cells. *PLoS Biol*. 2007; 5:e329. [PubMed: 18162042]
 96. Eberl G, Colonna M, Di Santo JP, McKenzie ANJ. Innate lymphoid cells. Innate lymphoid cells: a new paradigm in immunology. *Science*. 2015; 348:aaa6566. [PubMed: 25999512]
 97. Doherty TA, Khorram N, Lund S, Mehta AK, Croft M, Broide DH. Lung type 2 innate lymphoid cells express cysteinyl leukotriene receptor 1, which regulates TH2 cytokine production. *J Allergy Clin Immunol*. 2013; 132:205–13. [PubMed: 23688412]
 98. Chang Y-J, Kim HY, Albacker LA, Baumgarth N, McKenzie ANJ, Smith DE, et al. Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. *Nat Immunol*. 2011; 12:631–8. [PubMed: 21623379]
 99. Mjösberg JM, Trifari S, Crellin NK, Peters CP, van Drunen CM, Piet B, et al. Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CCR2 and CD161. *Nat Immunol*. 2011; 12:1055–62. [PubMed: 21909091]
 100. Roediger B, Kyle R, Yip KH, Sumaria N, Guy TV, Kim BS, et al. Cutaneous immunosurveillance and regulation of inflammation by group 2 innate lymphoid cells. *Nat Immunol*. 2013; 14:564–73. [PubMed: 23603794]
 101. Walker JA, Barlow JL, McKenzie ANJ. Innate lymphoid cells--how did we miss them? *Nat Rev Immunol*. 2013; 13:75–87. [PubMed: 23292121]
 102. Halim TYF, Steer CA, Mathä L, Gold MJ, Martinez-Gonzalez I, McNagny KM, et al. Group 2 innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell-mediated allergic lung inflammation. *Immunity*. 2014; 40:425–35. [PubMed: 24613091]
 103. Molofsky AB, Van Gool F, Liang H-E, Van Dyken SJ, Nussbaum JC, Lee J, et al. Interleukin-33 and Interferon- γ Counter-Regulate Group 2 Innate Lymphoid Cell Activation during Immune Perturbation. *Immunity*. 2015; 43:161–74. [PubMed: 26092469]
 104. Hoyler T, Klose CSN, Souabni A, Turqueti-Neves A, Pfeifer D, Rawlins EL, et al. The transcription factor GATA-3 controls cell fate and maintenance of type 2 innate lymphoid cells. *Immunity*. 2012; 37:634–48. [PubMed: 23063333]
 105. Liang H-E, Reinhardt RL, Bando JK, Sullivan BM, Ho I-C, Locksley RM. Divergent expression patterns of IL-4 and IL-13 define unique functions in allergic immunity. *Nat Immunol*. 2012; 13:58–66. [PubMed: 22138715]
 106. Lee J-B, Chen C-Y, Liu B, Mugge L, Angkasekwinai P, Facchinetti V, et al. IL-25 and CD4(+) TH2 cells enhance type 2 innate lymphoid cell-derived IL-13 production, which promotes IgE-mediated experimental food allergy. *J Allergy Clin Immunol*. 2016; 137:1216–1225. [PubMed: 26560039]
 107. Noval Rivas M, Burton OT, Oettgen HC, Chatila TA. IL-4 Production by Group 2 Innate Lymphoid cells Promotes Food Allergy by Blocking Regulatory T cell Function. *J Allergy Clin Immunol*. Article in press.
 108. Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. *PNAS*. 2008; 105:10113–8. [PubMed: 18635688]

109. Wakkach A, Fournier N, Brun V, Breittmayer J-P, Cottrez F, Groux H. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. *Immunity*. 2003; 18:605–17. [PubMed: 12753738]
110. Ito T, Yang M, Wang Y-H, Lande R, Gregorio J, Perng OA, et al. Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. *J Exp Med*. 2007; 204:105–15. [PubMed: 17200410]
111. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctlα4. *Science*. 1995; 270:985–8. [PubMed: 7481803]
112. Girtsman T, Jaffar Z, Ferrini M, Shaw P, Roberts K. Natural Foxp3(+) regulatory T cells inhibit Th2 polarization but are biased toward suppression of Th17-driven lung inflammation. *J Leukoc Biol*. 2010; 88:537–46. [PubMed: 20495073]
113. Curotto de Lafaille MA, Muriglan S, Sunshine MJ, Lei Y, Kutchukhidze N, Furtado GC, et al. Hyper immunoglobulin E response in mice with monoclonal populations of B and T lymphocytes. *J Exp Med*. 2001; 194:1349–59. [PubMed: 11696599]
114. Lim HW, Hillsamer P, Banham AH, Kim CH. Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells. *J Immunol*. 2005; 175:4180–3. [PubMed: 16177055]
115. Krishnamoorthy N, Khare A, Oriss TB, Raundhal M, Morse C, Yarlagadda M, et al. Early infection with respiratory syncytial virus impairs regulatory T cell function and increases susceptibility to allergic asthma. *Nature Med*. 2012; 18:1525–30. [PubMed: 22961107]
116. Koch MA, Thomas KR, Perdue NR, Smigiel KS, Srivastava S, Campbell DJ. T-bet(+) Treg cells undergo abortive Th1 cell differentiation due to impaired expression of IL-12 receptor β2. *Immunity*. 2012; 37:501–10. [PubMed: 22960221]
117. Zheng Y, Chaudhry A, Kas A, deRoos P, Kim JM, Chu T-T, et al. Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. *Nature*. 2009; 458:351–6. [PubMed: 19182775]
118. Komatsu N, Okamoto K, Sawa S, Nakashima T, Oh-hora M, Kodama T, et al. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. *Nature Med*. 2014; 20:62–8. [PubMed: 24362934]
119. Charbonnier L-M, Wang S, Georgiev P, Sefik E, Chatila TA. Control of peripheral tolerance by regulatory T cell-intrinsic Notch signaling. *Nat Immunol*. 2015; 16:1162–73. [PubMed: 26437242]
120. Tachdjian R, Khatib Al S, Schwinglshackl A, Sook Kim H, Chen A, Blasioli J, et al. In vivo regulation of the allergic response by the IL-4 receptor α chain immunoreceptor tyrosine-based inhibitory motif. *J Allergy Clin Immunol*. 2010; 125:1128–8. [PubMed: 20392476]
121. Mathias CB, Hobson SA, Garcia-Lloret M, Lawson G, Poddighe D, Freyschmidt E-J, et al. IgE-mediated systemic anaphylaxis and impaired tolerance to food antigens in mice with enhanced IL-4 receptor signaling. *J Allergy Clin Immunol*. 2011; 127:795–805. e1–6. [PubMed: 21167580]
122. Rudra D, deRoos P, Chaudhry A, Niec RE, Arvey A, Samstein RM, et al. Transcription factor Foxp3 and its protein partners form a complex regulatory network. *Nat Immunol*. 2012; 13:1010–9. [PubMed: 22922362]
123. Wang Y, Su MA, Wan YY. An Essential Role of the Transcription Factor GATA-3 for the Function of Regulatory T Cells. *Immunity*. 2011; 35:337–48. [PubMed: 21924928]
124. Hershey GK, Friedrich MF, Esswein LA, Thomas ML, Chatila TA. The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor. *N Engl J Med*. 1997; 337:1720–5. [PubMed: 9392697]
125. Rosa-Rosa L, Zimmermann N, Bernstein JA, Rothenberg ME, Khurana Hershey GK. The R576 IL-4 receptor alpha allele correlates with asthma severity. *J Allergy Clin Immunol*. 1999; 104:1008–14. [PubMed: 10550746]
126. Tachdjian R, Mathias C, Khatib Al S, Bryce PJ, Kim HS, Blaeser F, et al. Pathogenicity of a disease-associated human IL-4 receptor allele in experimental asthma. *J Exp Med*. 2009; 206:2191–204. [PubMed: 19770271]

127. Xia M, Viera-Hutchins L, Garcia-Lloret M, Noval Rivas M, Wise P, McGhee SA, et al. Vehicular exhaust particles promote allergic airway inflammation through an aryl hydrocarbon receptor-notch signaling cascade. *J Allergy Clin Immunol.* 2015; 136:441–53. [PubMed: 25825216]
128. Massoud AH, Charbonnier L-M, Lopez D, Pellegrini M, Phipatanakul W, Chatila TA. An asthma-associated *IL4R* variant exacerbates airway inflammation by promoting conversion of regulatory T cells to T_H17-like cells. *Nat Med.* 2016; 22:1013–22. DOI: 10.1038/nm.4147 [PubMed: 27479084]
129. Heederik D, Mutius von E. Does diversity of environmental microbial exposure matter for the occurrence of allergy and asthma? *J Allergy Clin Immunol.* 2012; 130:44–50. [PubMed: 22502794]
130. Wills-Karp M, Santeliz J, Karp CL. The germless theory of allergic disease: revisiting the hygiene hypothesis. *Nat Rev Immunol.* 2001; 1:69–75. [PubMed: 11905816]
131. Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N, et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. *PNAS.* 2010; 107:11971–5. [PubMed: 20566857]
132. Bager P, Wohlfahrt J, Westergaard T. Caesarean delivery and risk of atopy and allergic disease: meta-analyses. *Clin Exp Allergy.* 2008; 38:634–42. [PubMed: 18266879]
133. Braun-Fahrlander C, RIEDLER J, Herz U, EDER W, WASER M, GRIZE L, et al. Environmental exposure to endotoxin and its relation to asthma in school-age children. *N Engl J Med.* 2002; 347:869–77. [PubMed: 12239255]
134. Illi S, Illi S, Mutius von E, Erika von Mutius, Lau S, Lau S, et al. Early childhood infectious diseases and the development of asthma up to school age: a birth cohort study. *BMJ.* 2001; 322:390–5. [PubMed: 11179155]
135. Sudo N, Sawamura S, Tanaka K, Aiba Y, Kubo C, Koga Y. The requirement of intestinal bacterial flora for the development of an IgE production system fully susceptible to oral tolerance induction. *J Immunol.* 1997; 159:1739–45. [PubMed: 9257835]
136. Woo JG, Assa'ad A, Heizer AB, Bernstein JA, Hershey GK. The -159 C->T polymorphism of CD14 is associated with nonatopic asthma and food allergy. *J Allergy Clin Immunol.* 2003; 112:438–44. [PubMed: 12897754]
137. Bashir MEH, Louie S, Shi HN, Nagler-Anderson C. Toll-Like Receptor 4 Signaling by Intestinal Microbes Influences Susceptibility to Food Allergy. *J Immunol.* 2004; 172:6978–87. [PubMed: 15153518]
138. Penders J, Stobberingh EE, van den Brandt PA, Thijs C. The role of the intestinal microbiota in the development of atopic disorders. *Allergy.* 2007; 62:1223–36. [PubMed: 17711557]
139. Penders J, Thijs C, van den Brandt PA, Kummeling I, Snijders B, Stelma F, et al. Gut microbiota composition and development of atopic manifestations in infancy: the KOALA Birth Cohort Study. *Gut.* 2007; 56:661–7. [PubMed: 17047098]
140. Wang, Sen; Charbonnier, L-M.; Rivas, MN.; Georgiev, P.; Li, N.; Gerber, G., et al. MyD88 Adaptor-Dependent Microbial Sensing by Regulatory T Cells Promotes Mucosal Tolerance and Enforces Commensalism. *Immunity.* 2015; 43:289–303. [PubMed: 26231118]
141. Hill DA, Siracusa MC, Abt MC, Kim BS, Kobuley D, Kubo M, et al. Commensal bacteria-derived signals regulate basophil hematopoiesis and allergic inflammation. *Nature Med.* 2012; 18:538–46. [PubMed: 22447074]
142. Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. *PNAS.* 2010; 107:12204–9. [PubMed: 20566854]
143. Round JL, Lee SM, Li J, Jabri B, Chatila TA, Mazmanian SK. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. *Science.* 2011; 332:974–7. [PubMed: 21512004]
144. Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y, et al. Induction of colonic regulatory T cells by indigenous *Clostridium* species. *Science.* 2011; 331:337–41. [PubMed: 21205640]
145. Atarashi K, Tanoue T, Oshima K, Suda W, Nagano Y, Nishikawa H, et al. Treg induction by a rationally selected mixture of *Clostridia* strains from the human microbiota. *Nature.* 2013; 500:232–6. [PubMed: 23842501]

146. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. *Science*. 2013; 341:569–73. [PubMed: 23828891]
147. Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. *Nature*. 2013; 504:446–50. [PubMed: 24226770]
148. Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. *Nature*. 2013; 504:451–5. [PubMed: 24226773]
149. Trompette A, Gollwitzer ES, Yadava K, Sichelstiel AK, Sprenger N, Ngom-Bru C, et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. *Nature Med*. 2014; 20:159–66. [PubMed: 24390308]
150. Ohnmacht C, Park J-H, Cording S, Wing JB, Atarashi K, Obata Y, et al. Mucosal Immunology - The microbiota regulates type 2 immunity through ROR γ ⁺ T cells. *Science*. 2015; 349:989–93. [PubMed: 26160380]

What do we know?

- T_{Reg} cells have a key role in promoting and maintaining tolerance to allergens by regulating both innate and adaptive allergen-triggered immune response.
- Allergic diseases are associated with a failure to develop tolerance towards a specific allergen leading to the emergence of a pathogenic Th2 immune response.
- A pro-allergic inflammatory environment may skew allergen-specific T_{Reg} cells towards a pathogenic phenotype that perpetuates and aggravates disease.
- Allergic responses are influenced by the commensal flora, acting in part via T_{Reg} cells.

What is still unknown?

- Mechanisms by which T_{Reg} cells fail to maintain tolerance in allergic diseases are not well understood and require further investigation.




Fig 1. Natural and induced Foxp3⁺ T_{Reg} cells subsets

The T_{Reg} cell pool is composed by two different sub-populations, nT_{Reg} and iT_{Reg} cells, both expressing the transcription factor Foxp3 crucial for their development and regulatory functions. Foxp3⁺ Nrp-1^{high} Helios^{high} nT_{Reg} cells arise in the thymus and mediate tolerance to self- antigens. Foxp3⁺ Nrp-1^{low} Helios^{low} iT_{Reg} cells, which mediate tolerance to foreign antigens, are induced extra-thymically from naïve CD4⁺ Foxp3⁻ T_{conv} cells in the presence of TCR stimulation, TGF-β and RA by either CD103⁺ DCs at the intestinal mucosa or F4/80⁺ CD11c⁺ macrophages at the airways epithelial surfaces.




Fig 2. Mechanisms of Foxp3⁺ T_{Reg} cell-mediated suppression

Foxp3⁺ T_{Reg} cells mediate tolerance to allergens by diverse suppressive mechanisms. These include T cell cytolysis by a granzyme dependent mechanism, IL-2 deprivation, production of inhibitory cytokines including IL-10, IL-35 and TGF-β capable of blocking the proliferation of T_{eff} cells and down-modulation of antigen presenting cells (APCs) via LAG-3-MHC II and CTLA-4-CD80/CD86 interactions.




Fig 3. Regulation and suppression of allergic innate immune responses by T_{Reg} cells

T_{Reg} cells control innate immune cell subsets involved in promoting allergy. T_{Reg} cells block mast cell activation and the release of pre-formed anaphylactic mediators through OX40-OX40L mediated interactions. T_{Reg} cells also impede the IL-33-driven ILC2 expansion in the intestinal mucosa and their subsequent IL-4 production. Adapted version from the graphical abstract of ref. 107.




Fig 4. T_{Reg} cell mediated suppression of the adaptive allergic immune response
 T_{Reg} cells regulate allergen-specific Th2 immune responses and B cell IgE production. GITR stimulation of T_{Reg} cells increase their suppressive functions, leading to their blockade of naïve CD4⁺ T_{conv} cells conversion into allergen-specific Th2 T cells. T_{Reg} cells are also able to control B cells and block their IgE production by a direct CTLA-4 and cell contact-dependent mechanism and through the production of immunosuppressive cytokines such as IL-10.




Fig 5. Pathogenic “Th2 cell-like” T_{Reg} cell reprogramming in food allergy

Food allergy is characterized by a decreased induction of allergen-specific iT_{Reg} cells at the intestinal mucosa. Induced allergen-specific T_{Reg} cells in food allergic subjects are prone to acquire a pathogenic skewed “Th2-like” phenotype resulting in increased GATA-3 expression and IL-4 secretion. “Th2 cell-like” iT_{Reg} cells are dysfunctional and lacking in suppressor function. They are not able to control the T_{eff} Th2 cell immune response and mast cells expansion, perpetuating in the process the allergic phenotype.




Fig 6. Pathogenic “Th17 cell-like” T_{Reg} cell reprogramming by the IL-4R α -Q576R allele
 Human IL-4R α -Q576R is associated with increased asthma severity. Signalling through the IL4R α -Q576R on iT_{Reg} cells induces dual activation of STAT6 and STAT3, the latter through an autocrine IL-6 production loop. The IL-6-STAT3 axis promotes pathogenic “Th17 cell-like” T_{Reg} cell reprogramming resulting in ROR- γ t expression and IL-17 secretion by the reprogrammed T_{Reg} cells.




Fig 7. Microbiota-immune cell interactions shape oral tolerance

Metabolites, such as SFCAs produced by bacterial fermentation of dietary fibers promote the proliferation and *de novo* induction of iT_{Reg} cells through FFAR2 (GPR43) receptor and HDAC inhibition. Clostridial bacterial species promote the production of IL-22 by ROR- γ t ILC, reinforcing oral tolerance by decreasing gut permeability and oral allergen uptake. *Bacteroides Fragilis* production of PSA promotes *de novo* iT_{Reg} cells generation via TLR2 signalling. MyD88/STAT3-sensing by T_{Reg} cells enforces oral tolerance by inducing and directing the T_{FH} - T_{FReg} and IgA axis. The microbiota also promote the emergence of ROR- γ t expressing iT_{Reg} cells. ROR- γ t deficiency in T_{Reg} cells promotes a Th2 environment and oral allergen sensitization possibly by inducing iT_{Reg} cell reprogramming into “Th2 cell-like” cells expressing GATA-3.